SC 13D/A - NeueHealth, Inc. (0001671284) (Subject)
4 - NeueHealth, Inc. (0001671284) (Issuer)
4 - NeueHealth, Inc. (0001671284) (Issuer)
4 - NeueHealth, Inc. (0001671284) (Issuer)
Drove solid Q2 ‘24 results with continued focus on advancing value-driven model and delivering high-quality, consumer-centric care to all populations across the ACA Marketplace, Medicare, and Medicaid Delivered positive Adjusted EBITDA for the second consecutive quarter in 2024; reaffirming Adjusted EBITDA guidance for the full year Positioned for continued strong performance this year and beyond, expecting to reach high end of guidance range for consumers served by year-end NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today reported financial results for its second quarter ended June 30, 2024. "We continued to build momentum
NeueHealth, Inc. ("NeueHealth") (NYSE:NEUE), the value-driven healthcare company, today announced it will report Second Quarter financial results before the financial markets open on Wednesday, August 7, 2024, followed by a conference call at 8:00 AM Eastern Time. To participate via telephone, please pre-register at this link. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including dial-in number, conference number, and personal code that can be used to access the call. A webcast of the earnings call may also be accessed via NeueHealth's Investor Relations page at investors.neuehealth.com. The company suggests part
Significantly strengthens balance sheet, positioning Company for long-term, sustainable growth Underscores the value Company delivers to payors, providers, and consumers across the industry NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today announced that it entered into a secured loan facility for up to $150 million with Hercules Capital, Inc. (NYSE:HTGC) ("Hercules"). "This financing puts us in a strong position to advance our differentiated care model and take the lead as the industry continues to shift to value-based care," said Mike Mikan, President and CEO of NeueHealth. "We have established longstanding relationships with
8-K - NeueHealth, Inc. (0001671284) (Filer)
8-K - NeueHealth, Inc. (0001671284) (Filer)
8-K - NeueHealth, Inc. (0001671284) (Filer)
Drove solid Q2 ‘24 results with continued focus on advancing value-driven model and delivering high-quality, consumer-centric care to all populations across the ACA Marketplace, Medicare, and Medicaid Delivered positive Adjusted EBITDA for the second consecutive quarter in 2024; reaffirming Adjusted EBITDA guidance for the full year Positioned for continued strong performance this year and beyond, expecting to reach high end of guidance range for consumers served by year-end NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today reported financial results for its second quarter ended June 30, 2024. "We continued to build momentum
NeueHealth, Inc. ("NeueHealth") (NYSE:NEUE), the value-driven healthcare company, today announced it will report Second Quarter financial results before the financial markets open on Wednesday, August 7, 2024, followed by a conference call at 8:00 AM Eastern Time. To participate via telephone, please pre-register at this link. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including dial-in number, conference number, and personal code that can be used to access the call. A webcast of the earnings call may also be accessed via NeueHealth's Investor Relations page at investors.neuehealth.com. The company suggests part
Drove strong Q1 ‘24 results, focused on delivering coordinated, consumer-centric care to all populations through strong provider and payor partnerships and proactive consumer engagement Delivered Revenue of $245.1 million, Net Income from Continuing Operations of $5.7 million, Adjusted EBITDA of $2.5 million in Q1 ‘24, laying a solid foundation for continued profitable growth in 2024 NeueCare and NeueSolutions segments positioned for continued strong performance this year; maintaining expectation for 2024 Adjusted EBITDA of between $15 and $25 million† NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today reported financial result